A citation-based method for searching scientific literature

Zhenfang Du, Benjamin P Brown, Soyeon Kim, Donna Ferguson, Dean C Pavlick, Gowtham Jayakumaran, Ryma Benayed, Jean-Nicolas Gallant, Yun-Kai Zhang, Yingjun Yan, Monica Red-Brewer, Siraj M Ali, Alexa B Schrock, Ahmet Zehir, Marc Ladanyi, Adam W Smith, Jens Meiler, Christine M Lovly. Nat Commun 2021
Times Cited: 7







List of co-cited articles
17 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Clinical outcomes of EGFR kinase domain duplication to targeted therapies in NSCLC.
Jinguang Wang, Xingya Li, Xingyang Xue, Qiuxiang Ou, Xue Wu, Ying Liang, Xiaonan Wang, Ming You, Yang W Shao, Zhihong Zhang,[...]. Int J Cancer 2019
18
57

EGFR Kinase Domain Duplication (EGFR-KDD) Is a Novel Oncogenic Driver in Lung Cancer That Is Clinically Responsive to Afatinib.
Jean-Nicolas Gallant, Jonathan H Sheehan, Timothy M Shaver, Mark Bailey, Doron Lipson, Raghu Chandramohan, Monica Red Brewer, Sally J York, Mark G Kris, Jennifer A Pietenpol,[...]. Cancer Discov 2015
60
57

Mechanisms of receptor tyrosine kinase activation in cancer.
Zhenfang Du, Christine M Lovly. Mol Cancer 2018
190
42

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
Lecia V Sequist, Belinda A Waltman, Dora Dias-Santagata, Subba Digumarthy, Alexa B Turke, Panos Fidias, Kristin Bergethon, Alice T Shaw, Scott Gettinger, Arjola K Cosper,[...]. Sci Transl Med 2011
28

The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.
Matthew J Niederst, Haichuan Hu, Hillary E Mulvey, Elizabeth L Lockerman, Angel R Garcia, Zofia Piotrowska, Lecia V Sequist, Jeffrey A Engelman. Clin Cancer Res 2015
313
28


EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J Guillermo Paez, Pasi A Jänne, Jeffrey C Lee, Sean Tracy, Heidi Greulich, Stacey Gabriel, Paula Herman, Frederic J Kaye, Neal Lindeman, Titus J Boggon,[...]. Science 2004
28

Lung adenocarcinoma patient with an EGFR kinase domain duplication (KDD) and the response to icotinib.
You-Cai Zhu, Wen-Xian Wang, Chun-Wei Xu, Qing-He Tan, Jian-Ying Li, Wu Zhuang, Zheng-Bo Song, Kai-Qi Du, Gang Chen, Tang-Feng Lv,[...]. J Thorac Dis 2018
8
28

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska,[...]. N Engl J Med 2004
28



Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.
Kenneth S Thress, Cloud P Paweletz, Enriqueta Felip, Byoung Chul Cho, Daniel Stetson, Brian Dougherty, Zhongwu Lai, Aleksandra Markovets, Ana Vivancos, Yanan Kuang,[...]. Nat Med 2015
906
28

Mechanistic insights into the activation of oncogenic forms of EGF receptor.
Zhihong Wang, Patti A Longo, Mary Katherine Tarrant, Kwangsoo Kim, Sarah Head, Daniel J Leahy, Philip A Cole. Nat Struct Mol Biol 2011
70
28

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
28

Regulation of MAPKs by growth factors and receptor tyrosine kinases.
Menachem Katz, Ido Amit, Yosef Yarden. Biochim Biophys Acta 2007
284
28

A Novel Oncogenic Driver in a Lung Adenocarcinoma Patient Harboring an EGFR-KDD and Response to Afatinib.
Dong Chen, Xing-Liang Li, Biao Wu, Xiao-Bin Zheng, Wen-Xian Wang, Hua-Fei Chen, Yi-Yu Dong, Chun-Wei Xu, Mei-Yu Fang. Front Oncol 2020
4
50

EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.
Kartik Konduri, Jean-Nicolas Gallant, Young Kwang Chae, Francis J Giles, Barbara J Gitlitz, Kyle Gowen, Eiki Ichihara, Taofeek K Owonikoko, Vijay Peddareddigari, Suresh S Ramalingam,[...]. Cancer Discov 2016
57
28


Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Helena A Yu, Maria E Arcila, Natasha Rekhtman, Camelia S Sima, Maureen F Zakowski, William Pao, Mark G Kris, Vincent A Miller, Marc Ladanyi, Gregory J Riely. Clin Cancer Res 2013
14

Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation.
Geoffrey R Oxnard, Maria E Arcila, Camelia S Sima, Gregory J Riely, Juliann Chmielecki, Mark G Kris, William Pao, Marc Ladanyi, Vincent A Miller. Clin Cancer Res 2011
440
14

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.
Marina Chiara Garassino, Olga Martelli, Massimo Broggini, Gabriella Farina, Silvio Veronese, Eliana Rulli, Filippo Bianchi, Anna Bettini, Flavia Longo, Luca Moscetti,[...]. Lancet Oncol 2013
392
14

Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations.
Yusoo Lee, Tae Min Kim, Dong-Wan Kim, Soyeon Kim, Miso Kim, Bhumsuk Keam, Ja-Lok Ku, Dae Seog Heo. J Thorac Oncol 2019
13
14

The transcriptional landscape and mutational profile of lung adenocarcinoma.
Jeong-Sun Seo, Young Seok Ju, Won-Chul Lee, Jong-Yeon Shin, June Koo Lee, Thomas Bleazard, Junho Lee, Yoo Jin Jung, Jung-Oh Kim, Jung-Young Shin,[...]. Genome Res 2012
380
14

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer.
Ken Uchibori, Naohiko Inase, Mitsugu Araki, Mayumi Kamada, Shigeo Sato, Yasushi Okuno, Naoya Fujita, Ryohei Katayama. Nat Commun 2017
176
14

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.
Myung-Ju Ahn, Ji-Youn Han, Ki Hyeong Lee, Sang-We Kim, Dong-Wan Kim, Yun-Gyoo Lee, Eun Kyung Cho, Joo-Hang Kim, Gyeong-Won Lee, Jong-Seok Lee,[...]. Lancet Oncol 2019
33
14

A newly developed capture-based sequencing panel for genomic assay of lung cancer.
Sun-Wha Im, Jeesoo Chae, Se Song Jang, Jaeyong Choi, Jihui Yun, Soojin Cha, Nak-Jung Kwon, Yoon Kyung Jeon, Yoohwa Hwang, Miso Kim,[...]. Genes Genomics 2020
2
50

Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA).
Tomoya Kawaguchi, Masahiko Ando, Kazuhiro Asami, Yoshio Okano, Masaaki Fukuda, Hideyuki Nakagawa, Hidenori Ibata, Toshiyuki Kozuki, Takeo Endo, Atsuhisa Tamura,[...]. J Clin Oncol 2014
191
14

Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
Yong Jia, Cai-Hong Yun, Eunyoung Park, Dalia Ercan, Mari Manuia, Jose Juarez, Chunxiao Xu, Kevin Rhee, Ting Chen, Haikuo Zhang,[...]. Nature 2016
347
14

The biology and management of non-small cell lung cancer.
Roy S Herbst, Daniel Morgensztern, Chris Boshoff. Nature 2018
14

Epidermal growth factor receptor (EGFR) signaling in cancer.
Nicola Normanno, Antonella De Luca, Caterina Bianco, Luigi Strizzi, Mario Mancino, Monica R Maiello, Adele Carotenuto, Gianfranco De Feo, Francesco Caponigro, David S Salomon. Gene 2006
14




The SDF-1/CXCR4 chemokine axis in uveal melanoma cell proliferation and migration.
Jianjun Bi, Peng Li, Chuanyin Li, Jie He, Ying Wang, He Zhang, Xianqun Fan, Renbing Jia, Shengfang Ge. Tumour Biol 2016
12
14

Tumor-derived exosomes promote the in vitro osteotropism of melanoma cells by activating the SDF-1/CXCR4/CXCR7 axis.
Francesco Mannavola, Marco Tucci, Claudia Felici, Anna Passarelli, Stella D'Oronzo, Francesco Silvestris. J Transl Med 2019
23
14


Ligand-dependent tumor induction in medakafish embryos by a Xmrk receptor tyrosine kinase transgene.
C Winkler, J Wittbrodt, R Lammers, A Ullrich, M Schartl. Oncogene 1994
47
14

CXCR7 mediates SDF1-induced melanocyte migration.
Eunkyung Lee, Jiyeon Han, Kwangmi Kim, Hyunjung Choi, Eun-Gyung Cho, Tae Ryong Lee. Pigment Cell Melanoma Res 2013
35
14


Genome duplication in the teleost fish Tetraodon nigroviridis reveals the early vertebrate proto-karyotype.
Olivier Jaillon, Jean-Marc Aury, Frédéric Brunet, Jean-Louis Petit, Nicole Stange-Thomann, Evan Mauceli, Laurence Bouneau, Cécile Fischer, Catherine Ozouf-Costaz, Alain Bernot,[...]. Nature 2004
14

Zebrafish: Speeding Up the Cancer Drug Discovery Process.
Patricia Letrado, Irene de Miguel, Iranzu Lamberto, Roberto Díez-Martínez, Julen Oyarzabal. Cancer Res 2018
52
14

The Ras-Raf-MEK-ERK pathway in the treatment of cancer.
R A Hilger, M E Scheulen, D Strumberg. Onkologie 2002
204
14

Genetic progression of malignant melanoma.
J Tímár, L Vizkeleti, V Doma, T Barbai, E Rásó. Cancer Metastasis Rev 2016
32
14

MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT.
Zhan Zhang, Hong Sun, Hongyue Dai, Ryan M Walsh, Maki Imakura, Janell Schelter, Julja Burchard, Xudong Dai, Aaron N Chang, Robert L Diaz,[...]. Cell Cycle 2009
209
14



Tumor cell-produced matrix metalloproteinase 9 (MMP-9) drives malignant progression and metastasis of basal-like triple negative breast cancer.
Christine Mehner, Alexandra Hockla, Erin Miller, Sophia Ran, Derek C Radisky, Evette S Radisky. Oncotarget 2014
200
14

Casticin Inhibits A375.S2 Human Melanoma Cell Migration/Invasion through Downregulating NF-κB and Matrix Metalloproteinase-2 and -1.
Zih-Yun Wu, Jin-Cherng Lien, Yi-Ping Huang, Ching-Lung Liao, Jen-Jyh Lin, Ming-Jen Fan, Yang-Ching Ko, Yu-Ping Hsiao, Hsu-Feng Lu, Jing-Gung Chung. Molecules 2016
15
14

Signalling by the oncogenic receptor tyrosine kinase Xmrk leads to activation of STAT5 in Xiphophorus melanoma.
C Wellbrock, E Geissinger, A Gómez, P Fischer, K Friedrich, M Schartl. Oncogene 1998
32
14



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.